Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06581406RecruitingPhase 2/Phase 3
RP2 with nivolumab for untreated uveal melanoma
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges Any age - NCT06575530RecruitingPhase 4
Remimazolam for sedation after non-cardiac surgery
This trial tests a sedative called remimazolam besylate in patients who need a breathing tube and light sedation after non-cardiac surgery. The goal is to see if it works well and is safe.
Beijing, Beijing MunicipalityAges 18–64 - NCT06572267RecruitingPhase 2
Meplazumab for coronary artery disease
This trial tests if meplazumab can help people with chronic coronary syndrome who have stable angina. It focuses on patients with certain fatty deposits around their heart arteries that show up on a special CT scan.
Xi'an, ShannxiAges 18 years+ - NCT06579274RecruitingPhase 2
Parecoxib for pain after bleeding stroke study
This trial tests a pain medicine called parecoxib (injected into a vein) for people who have had a bleeding stroke around the brain (subarachnoid hemorrhage). It aims to see if it helps with pain without causing serious side effects.
Brno, Czech RepublicAges 18–85 - NCT06571149RecruitingPhase 4
Blood thinners and clot-busting drugs for stroke
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
EisenstadtAges 18 years+ - NCT06573411RecruitingPhase 4
Finerenone for primary membranous nephropathy
This trial tests if finerenone, a medicine that may protect the kidneys, can help people with primary membranous nephropathy (a kidney disease that causes protein in urine). It is for adults who are already taking a standard blood pressure medicine but still have protein in their urine.
Guangzhou, GuangdongAges 18 years+ - NCT06554301RecruitingPhase 1
Empagliflozin for pulmonary arterial hypertension study
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06554509RecruitingPhase 2/Phase 3
Study of SHR-1819 for prurigo nodularis
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06557616Recruiting
CoolCryo system for treating atrial fibrillation during mitral valve surgery
This trial tests a new tool called CoolCryo that freezes heart tissue to treat atrial fibrillation while you have mitral valve surgery. If you are already having this surgery and also have AF, this device could correct both problems at once.
BydgoszczAges 18 years+ - NCT06559176Enrolling by invitationPhase 1/Phase 2
Gene editing trial for chronic granulomatous disease
This trial tests a new gene editing treatment called PM359 for people with a specific type of chronic granulomatous disease (CGD) caused by a delGT mutation in the NCF1 gene. The goal is to see if it's safe and helps fight infections and inflammation.
Los Angeles, CaliforniaAges 6 years+ - NCT06562803Recruiting
Cleaning the blood for liver failure with sepsis
This trial tests if a special blood-filtering method combined with plasma exchange can help people with severe liver failure and sepsis. It aims to reduce inflammation and improve survival.
Guangzhou, GuangdongAges 18–70 - NCT06548360RecruitingPhase 3
Testing ruxolitinib cream for children with vitiligo
This study tests a cream called ruxolitinib for children with nonsegmental vitiligo. It aims to see if the cream can safely help restore skin color in affected areas.
Birmingham, AlabamaAges 2–11 - NCT06540833RecruitingPhase 2
Study of a new drug for psychosis in people with Alzheimer's disease
This trial tests an experimental medication to reduce hallucinations and delusions in people who have Alzheimer's disease. It may help manage these symptoms and improve quality of life for patients and their caregivers.
Anaheim, CaliforniaAges 55 years+ - NCT06549400Enrolling by invitationPhase 3
Study on long-term safety of mexiletine for myotonic dystrophy
This study tests if a daily capsule of mexiletine is safe and helpful over 26 weeks for people with myotonic dystrophy type 1 or 2. It's for people who finished a previous related study and want to continue treatment.
LeuvenAges 16 years+ - NCT06544499RecruitingPhase 3
Efgartigimod for adults with chronic ITP
This study tests an investigational drug called efgartigimod, given through a vein, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it safely raises platelet counts and reduces bleeding risk.
Phoenix, ArizonaAges 18 years+ - NCT06543992RecruitingPhase 2
Chemotherapy for breast cancer that spread to the brain lining
This trial tests a combination of two chemotherapy drugs (thiotepa and methotrexate) given directly into the fluid around your brain and spine through a small implanted device. It aims to treat breast cancer that has spread to the lining of the brain or spinal cord.
Nanjing, JiangsuAges 18–75 - NCT06549231RecruitingPhase 3
Rituximab and mycophenolate for scleroderma lung disease
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
ToursAges 18–100 - NCT03993262RecruitingPhase 2
Bortezomib for severe autoimmune encephalitis after rituximab
This Phase 2 study tests whether bortezomib can improve outcomes and safety in adults with severe autoimmune encephalitis. It focuses on people whose condition is confirmed by brain-related autoantibodies and who have already received rituximab.
München, BavariaAges 18 years+ - NCT05543447Recruiting
Safety and effectiveness of a brain blood-vessel device for aneurysms
This study tests how safe and effective the DERIVO 2heal device is for treating an intracranial (brain) aneurysm. You may be a candidate if you’re an adult with an aneurysm that doctors plan to treat with this specific device and you can safely take anti-platelet medicines.
AugsburgAges 18 years+ - NCT06037473Recruiting
PEG growth hormone for short stature in children
This trial tests if a long-acting growth hormone (PEGylated GH) helps children with various causes of short stature grow taller. It may be an option if your child has a condition like growth hormone deficiency, Turner syndrome, or idiopathic short stature.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT06519565RecruitingEarly Phase 1
Testing PRG-1801 for hard-to-treat immune thrombocytopenia
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
Wuhan, HubeiAges 18 years+ - NCT06528405RecruitingPhase 2
SGLT2 inhibitor study for acute kidney disease patients
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
TaipeiAges 18–80 - NCT06520397RecruitingPhase 4
Combination therapy vs. higher dose ustekinumab for Crohn's
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT06523400RecruitingPhase 3
Mexiletine for myotonic dystrophy types 1 and 2
This trial tests a once-daily drug called mexiletine PR to see if it can help reduce muscle stiffness (myotonia) in people with myotonic dystrophy type 1 or 2. It may be a good option if you have a confirmed genetic diagnosis and are at least 16 years old.
LeuvenAges 16 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.